Genetic Technologies Statistics
Total Valuation
GENE has a market cap or net worth of $9.61 million. The enterprise value is $7.42 million.
| Market Cap | 9.61M |
| Enterprise Value | 7.42M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GENE has 4.41 million shares outstanding.
| Shares Outstanding | 4.41M |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.50% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| Forward PS | n/a |
| PB Ratio | 3.06 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.08.
| Current Ratio | 1.67 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -480.22 |
Financial Efficiency
Return on equity (ROE) is -160.90% and return on invested capital (ROIC) is -285.91%.
| Return on Equity (ROE) | -160.90% |
| Return on Assets (ROA) | -105.50% |
| Return on Capital (ROIC) | -285.91% |
| Revenue Per Employee | $96,268 |
| Profits Per Employee | -$144,445 |
| Employee Count | 60 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 10.79 |
Taxes
| Income Tax | -6,730 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.87% in the last 52 weeks. The beta is 0.37, so GENE's price volatility has been lower than the market average.
| Beta (1Y) | 0.37 |
| 52-Week Price Change | -58.87% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 3.16 |
| Relative Strength Index (RSI) | 34.14 |
| Average Volume (30 Days) | 31,009 |
Short Selling Information
| Short Interest | 15,665 |
| Short Previous Month | 11,531 |
| Short % of Shares Out | 3.32% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.44 |
Income Statement
In the last 12 months, GENE had revenue of $5.78 million and -$8.67 million in losses. Loss per share was -$2.97.
| Revenue | 5.78M |
| Gross Profit | 2.97M |
| Operating Income | -9.69M |
| Pretax Income | -8.32M |
| Net Income | -8.67M |
| EBITDA | n/a |
| EBIT | -8.30M |
| Loss Per Share | -$2.97 |
Balance Sheet
The company has $2.43 million in cash and $249,416 in debt, giving a net cash position of $2.18 million or $0.50 per share.
| Cash & Cash Equivalents | 2.43M |
| Total Debt | 249,416 |
| Net Cash | 2.18M |
| Net Cash Per Share | $0.50 |
| Equity / Book Value | 3.14M |
| Book Value Per Share | 0.71 |
| Working Capital | 1.50M |
Cash Flow
In the last 12 months, operating cash flow was -$4.96 million and capital expenditures -$27,842, giving a free cash flow of -$4.99 million.
| Operating Cash Flow | -4.96M |
| Capital Expenditures | -27,842 |
| Free Cash Flow | -4.99M |
| FCF Per Share | -$25.93 |
Margins
Gross margin is 51.35%, with operating and profit margins of -167.74% and -150.04%.
| Gross Margin | 51.35% |
| Operating Margin | -167.74% |
| Pretax Margin | -144.01% |
| Profit Margin | -150.04% |
| EBITDA Margin | n/a |
| EBIT Margin | -143.71% |
| FCF Margin | -86.35% |
Dividends & Yields
GENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.00% |
| Shareholder Yield | -28.00% |
| Earnings Yield | -90.21% |
| FCF Yield | -51.92% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 14, 2023. It was a reverse split with a ratio of 1:5.
| Last Split Date | Dec 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
GENE has an Altman Z-Score of -27.76 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.76 |
| Piotroski F-Score | 1 |